Infectious disease

Association of Antiviral Prophylaxis and Rituximab Use with Post-transplant Lymphoproliferative Disorders (PTLD): A Nationwide Cohort Study

Association of Antiviral Prophylaxis and Rituximab Use with Post-transplant Lymphoproliferative Disorders (PTLD): A Nationwide Cohort Study

Recorded live on Tuesday, March 9, 2020, from 11:00 AM ET to 12:00 PM ET • Hosted by the AST Infectious Disease Community of Practice (IDCOP)

"Association of Antiviral Prophylaxis and Rituximab Use with Post-transplant Lymphoproliferative Disorders (PTLD): A Nationwide Cohort Study" (doi.org/10.1111/ajt.16423)

Watch Video

AST/AJT Journal Club hosted by IDCOP

AST/AJT Journal Club hosted by IDCOP

Tuesday, August 25, 2020, from 2:00 PM ET to 3:00 PM ET • Hosted by the Infectious Disease Community of Practice (IDCOP)

"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates."
(Am J Transplant. 2020 May 06. doi.org/10.1111/ajt.15976.)

In this article:
The most significant risk for developing Cytomegalovirus (CMV) infection after transplant depends upon donor (D) and recipient (R) CMV serostatus. In 2012, [an] Organ Procurement Organization (OPO) began a novel pretransplant CMV prevention strategy via matching deceased kidney donors and recipients by CMV serostatus... After the matching protocol, high‐risk D+R− were reduced from 18.5% to 2.9%, whereas low‐risk D−R− were increased from 13.5% to 24%. There was no adverse effect on transplant rates and no differential effect on waiting times for R+ vs R− after the protocol was implemented. [The authors believe this] protocol could be implemented on a regional or national level to optimize low and high‐risk CMV seroprofiles and potentially improve CMV‐related outcomes in kidney transplantation.

Speaker:
Joe Lockridge, MD • Portland VA Health Care System, Oregon Health and Science University, Portland, OR

Moderators:
Jennifer Chow, MD, MS • Tufts Medical Center, Boston, MA
Jonathan Maltzman, MD, PhD, FAST • Stanford University, Palo Alto, CA

AST/AJT Journal Clubs are free for both members and non-members. Pre-registration is required.

"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates"

"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates"

Recorded live on Tuesday, August 25, 2020 • Hosted by the Infectious Disease Community of Practice (IDCOP)

"Cytomegalovirus serologic matching in deceased donor kidney allocation optimizes high‐ and low‐risk (D+R− and D−R−) profiles and does not adversely affect transplant rates." (Am J Transplant. 2020 May 06. doi.org/10.1111/ajt.15976.)

Watch Video

AASLD-AST Webinar on COVID-19

AASLD-AST Webinar on COVID-19

Scheduled for Thursday, June 25, 2020 - 5:00 pm to 6:00 pm ET

CONTENT CONTRIBUTORS

  • AASLD COVID-19 Clinical Oversight Subcommittee
  • American Society of Transplantation

PRESENTERS

  • Alfred Sidney Barritt IV, MD, MSCR University of North Carolina at Chapel Hill
  • Olivia Kates, MD University of Washington

MODERATORS

  • Elizabeth C. Verna, MD, MS Columbia University Medical Center
  • Emily Blumberg, MD, FAST University of Pennsylvania

PANELISTS

  • Michael L. Schilsky, MD, FAASLD
  • Michael Ison, MD, MS
  • John C. Bucuvalas, MD, FAASLD

LEARN MORE

T3 WEBINAR: "Diagnostic Stewardship in Solid Organ Transplantation"

T3 WEBINAR: "Diagnostic Stewardship in Solid Organ Transplantation"

Speakers:
Angela Caliendo, MD, PhD • Professor of Medicine, Brown University, Providence, RI
Kimberly Hanson, MD, MHS • Associate Professor of Medicine and Pathology, University of Utah School of Medicine, Salt Lake City, UT

Moderator:
Deepali Kumar, MD, FRCPC, MSc • Associate Professor of Medicine, University of Toronto, Toronto, ON

AST would like to thank the Infectious Disease Community of Practice (IDCOP) and the Transplant Diagnostics Community of Practice (TxDx COP) for recommending diagnostic stewardship in infectious diseases as a topic for the 2019-2020 T3 series.

AST/AJT Journal Club hosted by the IDCOP

AST/AJT Journal Club hosted by the IDCOP

Tuesday, January 21, 2020 from 2:00 PM ET to 3:00 PM ET • Hosted by the Infectious Disease Community of Practice (IDCOP)

"Ultra-short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients."
(Am J Transplant. 2019 Oct 25. doi: 10.1111/ajt.15664. [Epub ahead of print]).

In this article:
[The authors] conducted an adaptive design single-center pilot trial between October 2017 and November 2018 to determine the safety and efficacy of ultra-short-term perioperative pangenotypic direct acting antiviral (DAA) prophylaxis for deceased hepatitis C virus (HCV)-nucleic acid test (NAT) positive donors to HCV negative kidney recipients (D+/R-).... At a median follow-up of 8 months posttransplant, overall patient and allograft survivals were 98%, respectively. The 4-day strategy reduced viral transmission to 7.5% (3/40; 95% confidence interval [CI]: 1.8%-20.5%) and could result in avoidance of prolonged posttransplant DAA therapy for most D+/R - transplants.

Speakers:
Gaurav Gupta, MD • Virginia Commonwealth University, Richmond, VA
Richard Sterling, MD • Virginia Commonwealth University, Richmond, VA

Moderator:
Deirdre Sawinski, MD, FAST • University of Pennsylvania Hospital, Philadelphia, PA

AST/AJT Journal Clubs are free to both AST and non-AST members, but registration is required. Please feel free to share the registration link with colleagues and fellows who may be interested in the discussion.

"Ultra-short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients"

"Ultra-short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients"

Originally aired on Tuesday, January 21, 2020 • Hosted by the Infectious Disease Community of Practice (IDCOP)

"Ultra-short Duration Direct Acting Anti-Viral Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic Donors to Hepatitis C Negative Kidney Transplant Recipients."
(Am J Transplant. 2019 Oct 25. doi: 10.1111/ajt.15664. [Epub ahead of print]).

Watch Video

AST/AJT Journal Club hosted by the IDCOP

AST/AJT Journal Club hosted by the IDCOP

Thursday, October 31st, 2019, from 2:00 PM ET to 3:00 PM ET • Hosted by the Infectious Disease Community of Practice (IDCOP)

"Risk factors for multidrug-resistant organisms among deceased organ donors."
(Am J Transplant. 2019 Jun 4. doi: 10.1111/ajt.15488.)

In this article:
[Through a multicenter retrospective cohort study, conducted at four transplant centers between 2015 and 2016, the authors] sought to determine the risk factors for MDROs among transplant donors. All deceased donors who donated at least one organ were included... This is the first study to determine risk factors for MDROs among deceased donors and will be important for risk stratifying potential donors and informing transplant recipient prophylaxis.

Speaker:
Judith Anesi, MD • University of Pennsylvania, Philadelphia, PA

Moderator:
Daniel Kaul, MD • University of Michigan, Ann Arbor, MI

AST/AJT Journal Clubs are free to both members and non-members. Pre-register today to support this IDCOP session, and please feel free to share the registration link with your colleagues!

AST/AJT Journal Club hosted by the PCOP

AST/AJT Journal Club hosted by the PCOP

Tuesday, September 17th, 2019, from 2:00 PM ET to 3:00 PM ET • Hosted by the Pediatric Community of Practice (PCOP)

"Absence of evidence that respiratory viral infections influence pediatric lung transplantation outcomes: Results of the CTOTC-03 study."
(Am J Transplant. 2019 Jun 19. doi: 10.1111/ajt.15505.)

In this article:
[After following] 61 pediatric lung transplant recipients for 2+ years or until they met a composite primary endpoint including bronchiolitis obliterans syndrome/obliterative bronchiolitis, retransplant, or death..., findings raise the possibility that the immunologic impact of CARV following pediatric lung transplant is different than that observed in adults.

Speaker:
Stuart Sweet, MD, PhD • Washington University in St. Louis, St. Louis, MO

Moderator:
Lara Danziger-Isakov, MD, MPH • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

AST/AJT Journal Clubs are free to both members and non-members. Pre-register today to support this Pediatric COP session, and please feel free to share the registration link with your colleagues!

Pages

Subscribe to RSS - Infectious disease